Eating Disorder Diagnostic Crossover: A Meta-Analysis
Abstract
Objective: Diagnostic crossover among eating disorders (EDs) is clinically important, yet rates are inconsistently quantified. This meta-analysis aims to quantify the frequency and direction of diagnostic crossover among EDs (both within-syndrome and between-syndrome), to evaluate study-level moderators of crossover rates, and to conduct a formal appraisal of the quality of the included studies.
Method: A literature search was conducted following PRISMA 2020 guidelines, including all relevant articles on PsycINFO, Pubmed/Medline, and ProQuest Dissertations & Theses Global databases from inception to June 10, 2026. Twenty-seven studies (24 samples; 287 effect sizes) were synthesized using random-effects models. Mixed-effects models tested diagnostic criteria, follow-up duration, treatment setting, diagnostic method, and demographics as moderators.
Results: Between-syndrome crossovers (e.g., bulimia nervosa [BN] to anorexia nervosa [AN]) were rare, ranging from 0% (e.g., AN to binge eating disorder [BED]) to 13% (e.g., BED to BN), whereas within-syndrome shifts such as AN subtype shifts (23% from restrictive to binge-purging type) and transitions into other specified feeding or eating disorder (OSFED)/eating disorder not otherwise specified (EDNOS) were more common (17% to 25% across syndromes). Diagnostic criteria and method were significant moderators.
Discussion: Diagnostic instability reflects within-AN shifts and OSFED/EDNOS transitions more than between-syndrome…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.